Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Increase of interferon-γ inducible CXCL9 and CXCL11 serum levels in patients with active Graves' disease and modulation by methimazole therapy.

Thyroid : official journal of the American Thyroid Association - 1 Nov 2013

Antonelli Alessandro, Ferrari Silvia Martina, Corrado Alda, Ferrannini Ele, Fallahi Poupak

Abstract excerpt

BACKGROUND: Chemokine (C-X-C motif) ligand (CXCL)9 and CXCL11 play an important role in the initial phases of autoimmune thyroiditis (AT); however, their serum levels in patients with Graves' disease (GD) have never been evaluated in relation to thyroid function and treatment. METHODS: To evaluate CXCL9 and CXCL11 serum levels in GD and to relate these parameters to the clinical phenotype, we measured CXCL9 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemokine CCL2
Share to Goiter

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Graves Disease

Share to Hyperthyroidism

Share to Immunologic Factors

Share to Interferon-gamma

Share to Recurrence

Share to Thyroid Gland

Source

Identifiers

PMID: 23721189
DOI: 10.1089/thy.2012.0485

Genes

CXCL11
CXCL9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Increase of interferon-γ inducible CXCL9 and CXCL11 serum levels in patients with active Graves' disease and modulation by methimazole therapy.PMID 23721189Read ↗

Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.Semantic proximity Read ↗

Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis.Semantic proximity Read ↗

Autoimmune thyroid disorders.Semantic proximity Read ↗

Association of the polymorphisms of chemokine genes (IL8, RANTES, MIG, IP10, MCP1 and IL16) with the pathogenesis of autoimmune thyroid diseases.Semantic proximity Read ↗

Increased interleukin-9 and Th9 cells in patients with refractory Graves' disease and interleukin-9 polymorphisms are associated with autoimmune thyroid diseases.Semantic proximity Read ↗

The phenotype of newly diagnosed Graves' disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study.Semantic proximity Read ↗

IGF1 deficiency in newly diagnosed Graves' disease patients.Semantic proximity Read ↗

Association of increased eomesodermin, BCL6, and granzyme B expression with major clinical manifestations of Hashimoto's thyroiditis - an observational study.Semantic proximity Read ↗

T lymphocyte activation in Graves' disease.Semantic proximity Read ↗

Serum immunoglobulin G4 levels and Graves' disease phenotype.Semantic proximity Read ↗

Effect of Interferon-γ on the Basal and the TNFα-Stimulated Secretion of CXCL8 in Thyroid Cancer Cell Lines Bearing Either the RET/PTC Rearrangement Or the BRAF V600e Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.